Please login to the form below

Not currently logged in
Email:
Password:

Dacogen

This page shows the latest Dacogen news and features for those working in and with pharma, biotech and healthcare.

Otsuka to buy cancer biopharma Astex

Otsuka to buy cancer biopharma Astex

Takes control of company behind Dacogen in $886m deal. Japanese pharma firm Otsuka has agreed to purchase cancer specialist Astex Pharmaceuticals in a deal worth $886m. ... Astex' lead product is Dacogen (decitabine), which is approved for the treatment

Latest news

  • Cancer data presented at ASCO

    Elsewhere, Eisai presented data concerning a phase III study of DNA methylation inhibitor Dacogen (decitabine) for injection in acute myeloid leukaemia (AML).

  • J&J positive about pipeline

    this month; and Dacogen (decitabine), currently sold as a treatment for myelodysplastic syndromes, for the new indication of acute myeloid leukaemia.

  • SuperGen and Astex to merge

    It plans to leverage a revenue stream from its product Dacogen, marketed in North America by Eisai and in the rest of the world by Johnson &Johnson.

  • New accounts: May

    Dacogen. Haematology. Darwin Grey. Midatech. Glyconanoparticles. Cancer vaccines. Healthcare Solutions. National Health Service.

  • The Pump House

    Dacogen (MGI Pharma). Myelodysplastic syndromes. US. Granisetron. Generic granisetron (Actavis Group).

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2013 Pharma deals during September 2013

    Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...